2 assets in GM1 Gangliosidosis

Therapeutic assets addressing GM1 Gangliosidosis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
az-3102 GM1 Gangliosidosis	Azafaros B.V.	P3	B (60)
Pbgm01 GM1 Gangliosidosis	Gemma Biotherapeutics	P1/2	CCC (48)